News tagged with monoclonal antibodies
Monoclonal antibody appears effective and safe in asthma Phase IIa trial
A novel approach to obstructing the runaway inflammatory response implicated in some types of asthma has shown promise in a Phase IIa clinical trial, according to U. S. researchers.
Diseases, Conditions, Syndromes
May 21, 2013 |
5 / 5 (1) |
0
Palivizumab cuts number of days of wheezing in preemies
(HealthDay)—Many pre-term babies suffer recurrent episodes of wheezing. Now, researchers say a common infection is a likely culprit and they may be able to prevent the breathing problems.
Diseases, Conditions, Syndromes
May 09, 2013 |
not rated yet |
0
|
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.
Cancer
May 02, 2013 |
not rated yet |
0
Study offers clues to making vaccine for infant respiratory illness
An atomic-level snapshot of a respiratory syncytial virus (RSV) protein bound to a human antibody represents a leap toward developing a vaccine for a common—and sometimes very serious—childhood disease. ...
Diseases, Conditions, Syndromes
Apr 25, 2013 |
not rated yet |
0
|
Patients with chronic fatigue use additional areas of brain when using memory
(Medical Xpress)—Scientists studying the brain scans of chronic fatigue patients have found they use additional brain regions to do simple tasks requiring attention. This may explain the problems many sufferers ...
Diseases, Conditions, Syndromes
Apr 23, 2013 |
5 / 5 (1) |
0
Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
Cancer
Apr 19, 2013 |
5 / 5 (2) |
0
|
Peptides for the treatment of severe diseases
A new class of drugs for the treatment of severe diseases such as cancer and autoimmune diseases is developed by the start-up Bicycle Therapeutics. The company is generating bicyclic peptides that can selectively ...
Medical research
Apr 15, 2013 |
5 / 5 (1) |
0
Engineered antibody demonstrated safety, efficacy in wide range of advanced tumors
(Medical Xpress)—The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR ...
Cancer
Apr 10, 2013 |
4 / 5 (1) |
0
Ranibizumab may prevent retinal detachment side effect
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, ...
Ophthalmology
Apr 09, 2013 |
5 / 5 (1) |
0
Monoclonal antibody targets, kills leukemia cells
Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells.
Cancer
Mar 25, 2013 |
5 / 5 (4) |
0
|
New monoclonal antibody developed that can target proteins inside cancer cells
Researchers have discovered a unique monoclonal antibody that can effectively reach inside a cancer cell, a key goal for these important anticancer agents, since most proteins that cause cancer or are associated with cancer ...
Cancer
Mar 13, 2013 |
5 / 5 (6) |
0
|
Investigational drug reduces heart damage during angioplasty
A single dose of an investigational anti-inflammatory drug, inclacumab, reduced damage to heart tissue during angioplasty in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Cardiology
Mar 12, 2013 |
not rated yet |
1
Clinical trial looks to improve pancreatic cancer survival rates
Researchers at Georgia Regents University Cancer Center are investigating a new avenue of treatment to help boost poor pancreatic cancer survival rates.
Cancer
Feb 12, 2013 |
not rated yet |
0
First human tests of meth medication completed
(Medical Xpress)—InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight ...
Medications
Dec 20, 2012 |
not rated yet |
0
|
Weekly dose reduces targeted drug's side effects, but not its activity against ALL
A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ...
Cancer
Dec 11, 2012 |
not rated yet |
0
Monoclonal antibodies
Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are identical because they are produced by one type of immune cell that are all clones of a single parent cell. Given almost any substance, it is possible to create monoclonal antibodies that specifically bind to that substance; they can then serve to detect or purify that substance. This has become an important tool in biochemistry, molecular biology and medicine. When used as medications, the generic drug name ends in -mab (see "Nomenclature of monoclonal antibodies").
For more information about Monoclonal antibodies, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
